News | February 22, 2023
Merck updates on Phase 3 MOVe-AHEAD trial evaluating Lagevrio
The safety profile of LAGEVRIO in this trial was generally consistent with that observed in previously reported clinical studies
The safety profile of LAGEVRIO in this trial was generally consistent with that observed in previously reported clinical studies
First release of Rs.166 crores incentives under PLI scheme for pharmaceuticals
Becomes the 1st diagnostics company in India to launch BD MAX MDR TB test
At commercial scale, Bluestem's patent pending technologies will reduce carbon emission by an estimated 75% or more and be cost-competitive with petroleum based chemicals
The new company will utilize Teijin's drug discovery research technologies, facilities, equipment and personnel.
New subgroup analysis from Phase III ARASENS trial shows that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel increased overall survival (OS)
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
Agasta Software is engaged in research, development and commercialization of medical devices
Cipla has received 8 inspectional observations in Form 483
Canagliflozin and Metformin Hydrochloride Tablets had annual sales of US $49.4 million in the United States
Subscribe To Our Newsletter & Stay Updated
